FTK, Flotek Industries Inc.

** On its third quarter fiscal 2011, FTK posted revenue of $75.1 million, an 87.7% increase year over year and net income attributable to common stockholders of $17.9 million, or $0.38 per common share (basic), compared to a net loss of $2.4 million, or ($0.09) per common share for the same period in 2010.

FTK is a global developer and distributor of innovative specialty chemicals and down-hole drilling and production equipment. FTK manages automated bulk material handling, loading and blending facilities. FTK serves major and independent companies in the domestic and international oilfield service industry.

More about FTK at www.flotekind.com.

******************

DVOX, Dynavox Inc.

** DVOX reported its first quarter fiscal year 2012 results, posting net sales of $26.2 million, a 21% year over year. Gross profit for the first quarter of fiscal year 2012 increased 24% to $19.0 million, compared to $15.3 million in the same period the prior year.

Acording to its fiscal year 2012 guidance, DVOX continues to project net sales to grow in the range of 3% to 7% from fiscal year 2011.

DVOX is the leading provider of speech generating devices and symbol-adapted special education software used to assist individuals in overcoming their speech, language and learning challenges. These solutions are designed to help individuals who have complex communication and learning needs participate in the home, classroom and community.

More about DVOX at www.dynavoxtech.com.

******************

ARWR, Arrowhead Research Corp.

** ARWR reported the publication of data from its majority-owned subsidiary Ablaris Therapeutics, Inc.'s lead drug candidate, Adipotide, demonstrating weight loss and reduction in body mass index and abdominal circumference in obese rhesus monkeys.

The data, which was published in Science Translational Medicine, demonstrates that monkeys treated with Adipotide lost an average of 11 percent of their body weight after only four weeks of treatment. In addition, Adipotide-treated animals showed marked improvements in insulin resistance (using about 60 percent less insulin after treatment compared to baseline), suggesting potential for use in treating type-2 diabetes.

ARWR is a nanomedicine company developing innovative therapies at the interface of biology and nanoengineering to cure disease and improve human health. ARWR is a leader in delivering small RNAs for gene silencing, and has programs in anti-obesity therapeutics and regenerative medicine.

More about ARWR at www.arrowheadresearch.com

**************************************************************

********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.